National Prescribing Indicators 2019–2020
Supporting Information for Prescribers and Healthcare Professionals

February 2019
This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG) and the All Wales Therapeutics and Toxicology Centre (AWTTC), and has subsequently been endorsed by the All Wales Medicines Strategy Group (AWMSG).

Please direct any queries to AWTTC:

All Wales Therapeutics and Toxicology Centre
University Hospital Llandough
Penlan Road
Llandough
Vale of Glamorgan
CF64 2XX

awttc@wales.nhs.uk
029 2071 6900

This document should be cited as:
CONTENTS

GLOSSARY ................................................................................................................................. 2
NOTES ........................................................................................................................................ 2
1.0 SAFETY INDICATORS ........................................................................................................ 3
  1.1 PRESCRIBING SAFETY INDICATORS ........................................................................... 3
  1.2 PROTON PUMP INHIBITORS .................................................................................... 5
  1.3 HYPNOTICS AND ANXIOLYTICS ............................................................................. 6
  1.4 ANALGESICS ........................................................................................................... 7
    1.4.1 OPIOID BURDEN ............................................................................................... 7
    1.4.2 TRAMADOL .......................................................................................................... 9
    1.4.3 GABAPENTIN AND PREGABALIN .................................................................. 10
  1.5 YELLOW CARDS ....................................................................................................... 11
2.0 ANTIMICROBIAL STEWARDSHIP INDICATORS .............................................................. 12
  2.1 TOTAL ANTIBACTERIAL ITEMS ............................................................................... 12
  2.2 4C ANTIMICROBIALS ............................................................................................... 13
3.0 EFFICIENCY INDICATORS ............................................................................................... 14
  3.1 BIOSIMILARS ................................................................................................................ 14
  3.2 INSULIN ....................................................................................................................... 15
GLOSSARY

ADQ – average daily quantity
ADRs – adverse drug reactions
AEC – Anticholinergic Effect on Cognition
AWMSG – All Wales Medicines Strategy Group
AWTTC – All Wales Therapeutics and Toxicology Centre
CEPP – Clinical Effectiveness Prescribing Programme
CHC – combined hormonal contraceptive
CKD – chronic kidney disease
DDD – defined daily dose
DVLA – Driver and Vehicle Licensing Agency
eGFR – estimated glomerular filtration rate
HCAI – healthcare associated infection
MHRA – Medicines and Healthcare products Regulatory Agency
MRSA – methicillin-resistant *Staphylococcus aureus*
NICE – National Institute for Health and Care Excellence
NPH – neutral protamine Hagedorn
NPIs – National Prescribing Indicators
NSAIDs – non-steroidal anti-inflammatory drugs
PHE – Public Health England
PHW – Public Health Wales
PPIs – proton pump inhibitors
PU – prescribing unit
RCOA – Royal College of Anaesthetists
RCGP – Royal College of General Practitioners
SSRIs – selective serotonin reuptake inhibitors
STAR-PU – specific therapeutic group age-sex related prescribing unit
UDG – user-defined group
WAPSU – Welsh Analytical Prescribing Support Unit
WeMeReC – Welsh Medicines Resource Centre
YCC – Yellow Card Centre

NOTES
Implementation of the NPIs does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
1.0 SAFETY INDICATORS

1.1 PRESCRIBING SAFETY INDICATORS

**Purpose:** To identify patients at high risk of ADRs and medicines-related harm in primary care.

**Unit of measure:**
- Patients with a peptic ulcer who have been prescribed NSAIDs without a PPI as a % of all patients.
- Patients with asthma who have been prescribed a beta-blocker as a % of all patients.
- Patients with concurrent prescriptions of verapamil and a beta-blocker as a % of all patients.
- Female patients with a past medical history of venous or arterial thrombosis who have been prescribed CHCs, as a % of all female patients.
- Female patients with a current prescription of oestrogen-only hormone replacement therapy without any hysterectomy READ/SNOMED codes, as a % of all female patients.
- Patients with concurrent prescriptions of warfarin and an oral NSAID as a % of all patients.
- Patients under 12 with a current prescription of aspirin as a % of all patients.
- Patients aged 65 years or over prescribed an NSAID plus aspirin and/or clopidogrel but without gastroprotection (PPI or H₂ receptor antagonist), as a % of all patients aged 65 years or over.
- Patients aged 65 years or over prescribed an antipsychotic, as a % of all patients aged 65 years or over.
- Patients aged 75 and over with an AEC score of 3 or more for items on active repeat, as a % of all patients aged 75 and over.
- Patients on the CKD register (CKD stage 3–5) who have received a repeat prescription for an NSAID within the last 3 months, as a % of all patients on the CKD register.
- Patients who are not on the CKD register but have an eGFR of < 59 ml/min and have received a repeat prescription for an NSAID within the last 3 months, as a % of all patients who are not on the CKD register but have an eGFR of < 59 ml/min.
- Female patients aged 14–45 with a prescription for sodium valproate as a % of all patients with a prescription for sodium valproate.

**Why is this important?**
- This NPI is facilitating the move towards a more patient-focused approach considering whether the right patients are getting the right medicines. This is intended to reduce the number of ADRs experienced by patients.
- In the UK, it is estimated that up to around 6.5% of hospital admissions are related to ADRs.
- ADRs can often be predictable, making it possible to identify potential causes and address them before actual patient harm occurs. Therefore a process of identifying patients electronically could enable intervention and help avoid harm.
- The PINCER study demonstrated that such an approach is an effective method for reducing the frequency of a range of medication errors.

**How can changes be made?**
- Review patients identified as being at high risk of ADRs and medicines-related harm ensuring that action taken is clearly documented and coded appropriately.
### What resources are available?

- AWMSG (2018) *Antipsychotics in dementia audit*
- MHRA (2014) *Antipsychotics learning module*
- WeMeReC (2015) *Medicines-related admissions*
- PrescQIPP (2016) *Bulletin 140: Anticholinergic drugs*
- AWMSG (2015) *CEPP All Wales Audit: Towards Appropriate NSAID Prescribing*
- AWMSG (2017) *CEPP National Audit: Medicines Management for CKD*
- Sanofi (2018) *Guide for healthcare professionals: Information on the risks of valproate use in girls (of any age) and women of childbearing potential*
1.2 PROTON PUMP INHIBITORS

Purpose: To encourage appropriate use of proton pump inhibitors (PPIs) in primary care.

Unit of measure: PPI DDDs per 1,000 PUs.

Why is this important?
- Safety concerns associated with long-term PPI use have been raised, e.g. C. difficile infection, fractures and hypomagnesaemia.
- Other possible serious adverse effects include acute interstitial nephritis, vitamin B₁₂ deficiency and rebound acid hypersecretion syndrome.

How can changes be made?
- When initiating a PPI, only consider for short courses (4 weeks) where needed, using acute, rather than repeat, prescriptions.
- Review long-term PPI prescriptions at least annually, and advise patients that it may be appropriate for them to return to self-treatment with antacid and/or alginate therapy.
- Inform patients of the potential long-term effects of PPIs as this may result in them being more willing to try self-care to improve their symptoms.
- Use the AWMSG patient information leaflet ‘Stopping Your PPI’ when initiating; reducing and stopping PPIs.
- Use the PPI audit and review toolkit in AWMSG Safe Use of Proton Pump Inhibitors resource pack.

What resources are available?
- AWMSG (2018) Safe Use of Proton Pump Inhibitors
- WeMeReC (2015) Proton pump inhibitors bulletin
- WeMeReC (2010) Stopping Medicines - Proton Pump Inhibitors
1.3 HYPNOTICS AND ANXIOLYTICS

Purpose: To encourage a reduction in the inappropriate prescribing of hypnotics and anxiolytics in primary care.

Unit of measure: Hypnotic and anxiolytic UDG ADQs per 1,000 STAR-PUs

Why is this important?
- There is a high level of hypnotic and anxiolytic prescribing in NHS Wales, compared with England.
- The problems associated with benzodiazepines (e.g. tolerance, dependence, withdrawal causing rebound insomnia) are well known, and the number of deaths associated with benzodiazepines has increased.
- Hypnotics and anxiolytics are known to significantly increase the risk of falls.

How can changes be made?
- Consider hypnotics only after non-drug therapies have been explored.
- When prescribing hypnotics, use the lowest dose possible, for the shortest duration possible and in strict accordance with their licensed indications: no more than 4 weeks.
- Do not offer benzodiazepines for the treatment of generalised anxiety disorder except as a short-term measure during crises.
- Always consider reducing hypnotics and anxiolytics where appropriate.
- Carry out the hypnotic and anxiolytic audit from the AWMSG Educational Pack: Materials to Support Appropriate Prescribing of Hypnotics and Anxiolytics across Wales.
- Use the hypnotic and anxiolytic reduction/withdrawal resources in the AWMSG Educational Pack: Materials to Support Appropriate Prescribing of Hypnotics and Anxiolytics across Wales.

What resources are available?
- AWMSG (2016) Educational Pack: Material to Support Appropriate Prescribing of Hypnotics and Anxiolytics across Wales
- WeMeReC (2015) Bulletin: Sedative medicines in older people
- AWMSG (2014) Polypharmacy: Guidance for Prescribing
- WeMeReC (2009) Stopping Medicines – benzodiazepines
### 1.4 ANALGESICS

#### 1.4.1 OPIOID BURDEN

**Purpose:** To encourage the appropriate use and review of all opioids in primary care, minimising the potential for dependence, diversion, misuse and ADRs.

**Unit of measure:** Opioid burden UDG ADQs per 1,000 patients

<table>
<thead>
<tr>
<th>Why is this important?</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The prescribing of opioids is often not the most appropriate or effective treatment option for patients with chronic pain, and can risk exposing patients to unnecessary harm.</td>
</tr>
<tr>
<td>• Despite the lack of evidence for use in chronic non-cancer pain, research has found an escalation of strong opioid prescribing in primary care, predominantly for non-cancer patients.</td>
</tr>
<tr>
<td>• Opioid analgesics have well established side effects including constipation, nausea and vomiting, and respiratory depression, and repeated administration may cause tolerance and dependence.</td>
</tr>
<tr>
<td>• Concerns about the harms caused by extensive prescribing of opioids have become particularly pertinent as a result of their extensive misuse in the USA.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>How can changes be made?</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Ensure that when prescribing opioids, consideration is given to: the benefits of treatment; the risks of prescribing, including dependency, overdose and diversion; all prescribed and non-prescribed medicines the person is taking, and whether the person may be opioid naïve.</td>
</tr>
<tr>
<td>• If it is thought opioid therapy may play a role in a patient’s pain management, a trial should be initiated to establish whether the patient achieves a reduction in pain with the use of opioids – if not they should be stopped.</td>
</tr>
<tr>
<td>• Dose escalation should be limited as risk of harm rises as dose increases, especially if there is inadequate relief of pain. Above an oral morphine equivalent daily dose of 120 mg, further benefit is unlikely.</td>
</tr>
<tr>
<td>• Use The RCoA Faculty of Pain Medicine checklist to aid discussions regarding opioid treatment with patients.</td>
</tr>
<tr>
<td>• Conduct a search to identify patients on an oral morphine equivalent daily dose of ≥120 mg in order to undertake reviews.</td>
</tr>
</tbody>
</table>
Opioid Equivalence Table (Values are approximate – see notes below)
Reproduced with kind permission from a resource developed by Emma Davies, Advanced Pharmacist Practitioner in Pain Management, Abertawe Bro Morgannwg UHB.

<table>
<thead>
<tr>
<th>Morphine</th>
<th>Oxycodeine</th>
<th>Fentanyl</th>
<th>Buprenorphine</th>
<th>Codeine phosphate/Dihydrocodeine</th>
<th>Tramadol</th>
<th>Tapentadol (Palexia® SR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (mg)</td>
<td>Oral (mg)</td>
<td>Transdermal patch (mcg/hr)</td>
<td>Transdermal patch (mcg/hr)</td>
<td>Oral (mg)</td>
<td>Oral (mg)</td>
<td>Oral (mg)</td>
</tr>
<tr>
<td>24hr total dose</td>
<td>24hr total dose</td>
<td>Patch strength STABLE PAIN ONLY</td>
<td>Patch strength STABLE PAIN ONLY</td>
<td>24hr total dose</td>
<td>24hr total dose</td>
<td>24hr total dose</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td>60</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td>120</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td>150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td>240</td>
<td>200</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td>300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td></td>
<td></td>
<td></td>
<td>400</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td></td>
<td></td>
<td></td>
<td>200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td>300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td></td>
<td></td>
<td></td>
<td>300</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Doses above this level are not recommended in chronic pain

If patient is still complaining of pain despite opioids at this level, then opioids are not working and should be reduced and stopped even if there is no other treatment available.

<table>
<thead>
<tr>
<th></th>
<th>Oxycodeine</th>
<th>Fentanyl</th>
<th>Buprenorphine</th>
<th>Codeine phosphate/Dihydrocodeine</th>
<th>Tramadol</th>
<th>Tapentadol (Palexia® SR)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oral (mg)</td>
<td>Oral (mg)</td>
<td>Oral (mg)</td>
<td>Oral (mg)</td>
<td>Oral (mg)</td>
<td>Oral (mg)</td>
</tr>
<tr>
<td>140</td>
<td>70</td>
<td>37</td>
<td></td>
<td>105</td>
<td></td>
<td></td>
</tr>
<tr>
<td>160</td>
<td>80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180</td>
<td>90</td>
<td>50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td>105</td>
<td></td>
</tr>
<tr>
<td>240</td>
<td>120</td>
<td>62</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>280</td>
<td>140</td>
<td>75</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>320</td>
<td>160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>360</td>
<td>180</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Each row is roughly equivalent e.g.: 60 mg bd oral morphine = 30 mg bd oral oxycodone = 25 mcg/hr fentanyl patch

NB: This is to be used as a guide rather than a set of definite equivalences. Some doses suggested may be ‘off-licence’, but are based on clinical experience. Refer to the Summary of Product Characteristics for further details. Most data on doses are based on single dose studies so it may be less accurate in chronic use where similar data are unavailable. Consider that individual patients may metabolise different drugs at varying rates. The advice is to always calculate doses using morphine as standard and to adjust them to suit the patient and the situation – consider making a reduction in morphine equivalence dose of 20–50% when changing drugs. Caution should be used in renal and hepatic failure. Avoid patch use in unstable pain.

What resources are available?

- MHRA Opioids e-learning module
- RCoA Faculty of Pain Medicine (2019) Opioids Aware: Tapering and stopping opioids
- AWMSG (2016) Persistent pain resources
- RCoA Faculty of Pain Medicine (2019) Opioids Aware
- RCoA Faculty of Pain Medicine (2019) Checklist for Prescribers
- WeMeReC (2010) Stopping compound medications containing codeine
1.4.2 TRAMADOL

**Purpose:** To encourage appropriate use and review of tramadol in primary care, minimising the potential for dependence, diversion, misuse and ADRs.

**Unit of measure:** Tramadol DDDs per 1,000 patients

<table>
<thead>
<tr>
<th>Why is this important?</th>
</tr>
</thead>
<tbody>
<tr>
<td>• While there is a recognised place in pain management for tramadol, there are concerns regarding abuse, dependence and deaths involving tramadol, in addition to the risks associated with misuse and diversion.</td>
</tr>
<tr>
<td>• Tramadol produces analgesia by two mechanisms: an opioid effect and an enhancement of the serotonergic and adrenergic pathways. This unique dual-action pharmacological profile of tramadol increases the risk of adverse effects seen in overdose.</td>
</tr>
<tr>
<td>• Hallucinations, confusion and convulsions, as well as rare cases of dependence and withdrawal symptoms, have been reported with tramadol at therapeutic doses.</td>
</tr>
<tr>
<td>• Tramadol should be used with caution in patients taking concomitant medicines that can lower the seizure threshold, such as tricyclic antidepressants or SSRIs. The use of tramadol is contra-indicated in uncontrolled epilepsy and in patients receiving, or who have recently discontinued (within the previous two weeks) monoamine oxidase inhibitors.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>How can changes be made?</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Use the AWMSG Tramadol Shared Decision Making Toolkit with patients when consideration is being given to prescribing tramadol.</td>
</tr>
<tr>
<td>• Provide patients with the AWMSG Tramadol Patient Information Leaflet where tramadol is initiated.</td>
</tr>
<tr>
<td>• If it is appropriate for a patient’s tramadol to be stepped down or stopped, reduce the dose slowly to ensure the patient’s safety and to minimise the risk of withdrawal symptoms and/or ADRs. Where physical dependence to tramadol develops, the withdrawal syndrome can be severe, with symptoms typical of opiate withdrawal sometimes accompanied by seizures, hallucinations and anxiety.</td>
</tr>
<tr>
<td>• To encourage patient engagement and concordance, a suggested approach would be to reduce the dose at each reduction step, e.g. by one 50 mg dose, and to titrate according to how the patient manages, rather than by setting time limits for the next reduction.</td>
</tr>
<tr>
<td>• Carry out the tramadol audit – AWMSG Tramadol Educational Resource Materials: Audit Materials.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>What resources are available?</th>
</tr>
</thead>
<tbody>
<tr>
<td>• AWMSG (2013) <a href="#">Tramadol Educational Resource Materials</a></td>
</tr>
<tr>
<td>• AWMSG (2013) <a href="#">Tramadol Audit Materials</a></td>
</tr>
<tr>
<td>• AWMSG (2013) <a href="#">Tramadol Shared Decision Making Toolkit</a></td>
</tr>
<tr>
<td>• AWMSG (2013) <a href="#">Tramadol Patient Information Leaflet</a></td>
</tr>
<tr>
<td>• AWMSG (2016) <a href="#">Persistent pain resources</a></td>
</tr>
</tbody>
</table>
1.4.3 GABAPENTIN AND PREGABALIN

**Purpose:** To encourage the appropriate use and review of gabapentin and pregabalin in primary care, minimising the potential for dependence, diversion, misuse and ADRs.

**Unit of measure:** Gabapentin and pregabalin DDDs per 1,000 patients

### Why is this important?
- While there is a recognised place in pain management for gabapentin and pregabalin, there are concerns regarding the risks associated with dependence, diversion and misuse.
- There has been an increase in the number of deaths where gabapentin or pregabalin was mentioned on the death certificate in England and Wales, from 12 deaths registered in 2012 to 196 deaths registered in 2017.

### How can changes be made?
- Use a pain scale (for example, the Leeds assessment of neuropathic symptoms and signs [LANSS]) to assess whether the patient’s pain is neuropathic in nature. This will also assist in determining response to treatment.
- Inform patients that response to drug treatment in neuropathic pain is often inadequate, with no more than 40–60% of people obtaining partial pain relief.
- Once treatment has commenced, NICE recommends early assessment followed by regular reviews to assess and monitor effectiveness including pain control, adverse effects and continued need.
- Reduce and stop the gabapentin or pregabalin if the patient has not shown sufficient benefit within eight weeks of reaching the maximum tolerated dose.
  - Gabapentin can be reduced over a minimum of one week; however, a more gradual dose taper by reducing the daily dose by a maximum of 300 mg every four days allows for emergent symptoms that may have been controlled by gabapentin.
  - Pregabalin can be reduced over a minimum of one week; however, a more gradual dose taper by reducing the daily dose by a maximum of 50–100 mg per week allows observation of emergent symptoms that may have been controlled by pregabalin.
- Exercise caution in prescribing gabapentin or pregabalin for patients with a history of substance abuse.

### What resources are available?
- The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale
- PrescQIPP (2016) Neuropathic pain: Pregabalin and gabapentin prescribing
- PHE (2014) Advice for prescribers on the risk of the misuse of pregabalin and gabapentin
- AWMSG (2016) Persistent pain resources
1.5 YELLOW CARDS

**Purpose:** To encourage an increase in the number of Yellow Cards submitted in Wales.

**Unit of measure:** Number of Yellow Cards submitted per GP practice, per health board and per hospital. Number of Yellow Cards submitted by Community Pharmacies, per health board.

**Why is this important?**
- ADRs are a significant clinical problem, increasing morbidity and mortality.
- The Yellow Card Scheme is vital in helping the MHRA monitor the safety of all healthcare products in the UK to ensure they are acceptably safe for those that use them.
- Yellow Card reporting supports the identification and collation of ADRs, which might not have been known about before.

**How can changes be made?**
- Yellow Card reports can be completed:
  - Online: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)
  - Using the free Yellow Card app
  - Through the Vision prescribing system.
  - By writing to FREEPOST YELLOW CARD
  - By emailing: [yellowcard@mhra.gov.uk](mailto:yellowcard@mhra.gov.uk)
  - By downloading forms from the website
- You only need to suspect that an adverse drug reaction was caused by a medicine to report it.
- Don’t assume someone else will report an adverse drug reaction you witness.
- Reports can be made for all medicines including vaccines, blood factors and immunoglobulins, herbal medicines and homeopathic remedies, and all medical devices available on the UK market.
- Sign up to make a [Yellow Card Support Pledge](#) and encourage colleagues and patients/carers to do the same.

**What resources are available?**
- Yellow Card champions are available in each health board to provide training. Contact [YCCWales@wales.nhs.uk](mailto:YCCWales@wales.nhs.uk) for more information
- Yellow Card reports can be completed online – [Yellow Card website](#)
- [Health Professional Guidance on Reporting](#)
- [MHRA web pages](#)
- [WeMeReC (2013) Pharmacovigilance Bulletin](#)
- [YCC Wales website](#)
- The Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) e-learning module: [Adverse Drug Reactions: Reporting makes medicines safer](#)
- [NHS Scotland e-learning modules on ADRs](#)
2.0 ANTIMICROBIAL STEWARDSHIP INDICATORS

2.1 TOTAL ANTIBACTERIAL ITEMS

**Purpose:** To encourage the appropriate prescribing of all antibiotics in primary care.

**Units of measure:**
Total antibacterial items per 1,000 STAR-PUs.

**Why is this important?**
- The widespread and often excessive usage of antimicrobials in one of the main factors contributing to the increasing emergence of antimicrobial resistance.

**How can changes be made?**
- Follow local or national guidelines, prescribing antibiotics for the shortest effective course at the most appropriate dose.
- Consider the risk of antimicrobial resistance for individual patients and the population as a whole.
- Document the clinical diagnosis (READ/SNOMED code to aid audit) and reason for prescribing, or not prescribing, an antimicrobial.
- Consider a delayed/back up prescription.
- Provide patients with leaflets/resources so they are aware of how long they can expect their condition to last and how they can self-care. Resources are available in the TARGET Antibiotics toolkit.
- Carry out the AWMSG National Audit: Focus on Antibiotic Prescribing.

**What resources are available?**
- AWMSG (2015) *Primary care antimicrobial guidelines*
- AWMSG (2013) *CEPP National Audit: Focus on Antibiotic Prescribing*
- WeMeReC (2012) *Bulletin: Appropriate antibiotic use – whose responsibility?*
- RCGP *TARGET Antibiotics toolkit*
2.2 4C ANTIMICROBIALS

**Purpose:** To reduce the prevalence of HCAI including *Clostridium difficile* infection and *Staphylococcus aureus* bacteraemia caused by MRSA by encouraging a reduction in variation and reduce overall prescribing of the 4C antimicrobials (co-amoxiclav, cephalosporins, fluoroquinolones and clindamycin) in primary care.

**Unit of measure:**
4C items combined, per 1,000 patients.

**Why is this important?**
- The use of simple generic antibiotics and the avoidance of broad-spectrum antibiotics (e.g. co-amoxiclav, cephalosporins, fluoroquinolones and clindamycin) preserve these from resistance and reduce the risk of *C. difficile*, MRSA and resistant urinary tract infections.
- Compared with narrow-spectrum antibiotics, broad-spectrum antibiotics are more likely to significantly change the gut flora, potentially allowing other bacteria, such as *C. difficile*, to become established.
- The most commonly implicated antibiotics in *C. difficile* infection include clindamycin, cephalosporins, fluoroquinolones and co-amoxiclav.

**How can changes be made?**
- Follow local or national guidelines, prescribing antibiotics for the shortest effective course at the most appropriate dose.
- Consider the risk of antimicrobial resistance for individual patients and the population as a whole.
- Document the clinical diagnosis (READ/SNOMED code to aid audit) and reason for prescribing, or not prescribing, an antimicrobial.
- Consider a delayed/back up prescription.
- Provide patients with leaflets/resources so they are aware of how long they can expect their condition to last and how they can self-care. Resources are available in the TARGET Antibiotics toolkit.
- Carry out the AWMSG National Audit: Focus on Antibiotic Prescribing.

**What resources are available?**
- AWMSG (2015) Primary care antimicrobial guidelines
- AWMSG (2013) CEPP National Audit: Focus on Antibiotic Prescribing
- WeMeReC (2012) Bulletin: Appropriate antibiotic use – whose responsibility?
- RCGP TARGET Antibiotics toolkit
3.0 EFFICIENCY INDICATORS

3.1 BIOSIMILARS

Purpose: To ensure prescribing of biological medicines supports cost-efficient prescribing in primary and secondary care in Wales.

Unit of measure: Quantity of biosimilar medicines prescribed as a percentage of total ‘reference’ product plus biosimilar.

Why is this important?

- Biological medicines account for a significant expenditure in NHS Wales.
- Biosimilar medicines are biological medicines that have been developed as highly similar and clinically equivalent to their ‘reference’ or ‘originator’ medicine.
- A number of reference biological medicines have recently lost their patent protection, or will lose it within the next five years, creating opportunities for increased commercial competition.
- Although individual health boards’ contracting prices, as well as national contracting prices, for biosimilar and reference medicines may vary, there are expected to be significant cost-saving opportunities from the use of the most cost-efficient biological medicine.

How can changes be made?

- Where AWMSG or NICE has recommended the reference medicine, the same guidance will normally apply to the biosimilar.
- At the time of dispensing there must not be automatic substitution of the reference product with a biosimilar medicine. Therefore, the clinician in consultation with the patient should make the decision on whether the reference or biosimilar biological medicine will be prescribed for the patient.
- All biological medicines, including biosimilars, must be prescribed by brand name.
- Current biological medicines with biosimilar versions for use in NHS Wales that will be reported on for the NPI in 2019–2020 are:
  - Infliximab – Inflectra®
  - Etanercept – Benepali®, Erelzi®,
  - Rituximab – Truxima®,
  - Trastuzumab – Ontruzant®,
  - Adalimumab – Amgevita®, Hulio®, Hyrimoz®, Imraldi®

What resources are available?

- AWTTC (2018) SPIRA – Biosimilar Efficiencies
- EMA (2017) Biosimilars in the EU
- The Cancer Vanguard (2017) Biosimilars frequently asked questions for healthcare professionals
- AWMSG Position statement for biosimilar medicines
- NICE Position statement for biosimilar medicines
- NICE (2018) Key Therapeutic Topic 15: Biosimilar medicines
- EMA (2018) European public assessment reports
- The Cancer Vanguard Biosimilars adoption resources
3.2 INSULIN

**Purpose:** To encourage a reduction in the prescribing of long-acting insulin analogues in primary and secondary care in line with NICE guidance to maximise cost-effectiveness in Wales.

**Unit of measure:** Items/number of long-acting insulin analogues as a percentage of total long- and intermediate-acting insulin prescribed.

### Why is this important?
- In type 2 diabetes mellitus when blood glucose control is inadequate on oral anti-diabetic therapy, insulin should be considered as the next treatment option.
- Human isophane (NPH) insulin is recommended as the first choice regimen.
- There is an absence of evidence to suggest superiority of the long-acting insulin analogues over NPH insulin.

### How can changes be made?
- Patients should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. Discuss with the patient the comparative effectiveness of the specific insulin types and ascertain any preference.
- When patients are started on an insulin therapy, a structured programme of active dose titration should be employed. In addition, this programme should also cover injection technique, continuing telephone support, self-monitoring, dietary understanding, DVLA guidance, management of hypoglycaemia, management of acute changes in plasma glucose control, and support from an appropriately trained and experienced healthcare professional.

### What resources are available?
- NICE (2015) [NG28: Type 2 diabetes in adults: management](https://www.nice.org.uk/guidance/ng28)
- Cochrane (2007) [Long-acting analogues versus NPH insulin](https://www.cochranelibrary.com)